A Phase II Study of Paclitaxel in Advanced Breast Cancer Resistant to Anthracyclines

European Journal of Cancer

Volumn 32, Issue 1, 1996, Pages 47-51

  Fountzilas, G ^a   Athanassiades, A ^a   Giannakakis, T ^b   Bafaloukos, D ^c   Karakousis, K ^a   Dombros, N ^a   Kosmidis, P ^c   Skarlos, D ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

Author keywords

Anthracycline; Breast cancer; Paclitaxel

Indexed keywords

ANTHRACYCLINE DERIVATIVE; MITOXANTRONE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PACLITAXEL; SURVIVAL RATE;

EID: 0029983116     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00398-3     Document Type: Article

References (22)

1. Buzdar AV, Legha S, Hortobagyi G, et al. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin containing regimens. Cancer 1981, 47, 2798-2802.
2. Kosmidis P, Kondylis D, Lissaios B. Salvage chemotherapy for breast cancer patients treated with adjuvant adriamycin-containing regimen. Oncology 1990, 47, 1-3.
3. Wall ME, Wani MC. Antineoplastic agents from plants. Ann Rev Pharmacol Toxicol 1977, 17, 117-132.
4. Schiff PB, Fant J, Horowitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 665-667.
5. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981, 256, 10435-10441.
6. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83, 1797-1805.
7. Reichman BS, Seidman AD, Crown JPA, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993, 11, 1943-1951.
8. Seidman AD. Single agent use of TAXOL (paclitaxel) in breast cancer. Ann Oncol 1994, 5 (suppl 6), S17-S22.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
10. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1985, 53, 229-232.
11. Cabral FR. Isolation of Chinese hamster ovarian cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 1983, 97, 22-29.
12. Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Inst Monog 1993, 15, 63-67.
13. Moscow JA, Cowan KH. Multidrug resistance. J Natl Cancer Inst 1988, 80, 14-20.
14. Seidman AD, Crown JPA, Reichman BS, et al. Lack of clinical cross-resistance of Taxol with anthracycline in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1993, 12, 63 (abstract 53).
15. Nabholtz JM, Gelmon K, Bontenbal M, et al. Randomized trial of two doses of taxol in metastatic breast cancer: an interim analysis (Abstr). Proc Am Soc Clin Oncol 1993, 12, 60.
16. Munzone E, Capri G, Demicheli R, et al. Activity of Taxol by 3 h infusion in breast cancer patients with clinical resistance to anthracyclines. Eur J Cancer 1993, 29A (suppl 6), S79 (abstract 413).
17. Vermorken JB, Huizing MZT, Liefting AJM, et al. High-dose taxol with G-CSF in patients with advanced breast cancer refractory to anthracycline therapy. Eur J Cancer 1993, 29A (suppl 6), S83 (abstract 435).
18. Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994, 12, 1621-1629.
19. Rowinsky EK, Chaudhry V, Forastiere AA, et al. A phase II and pharmacologic study of taxol and cisplatin with granulocyte colony-stimulating factor. Neuromuscular toxicity is dose-limiting. J Clin Oncol 1993, 11, 2010-2020.
20. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989, 39, 368-373.
21. McGuire WP, Rowinsky EK, Rosenhein NB, et al. Taxol. A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989, 111, 273-279.
22. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991, 9, 1692-1703.